Cognitive impairment and dementia in Parkinson's disease: Practical issues and management

Movement Disorders

Volumn 29, Issue 5, 2014, Pages 663-672

  Emre, Murat ^a   Ford, Paul J ^b   Bilgiç, Başar ^a   Uç, Ergun Y ^c,d  

^a ISTANBUL UNIVERSITY   (Turkey)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cognitive impairment; Decision making capacity; Dementia; Driving; Ethics; Parkinson's disease

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CHOLINESTERASE INHIBITOR; CITALOPRAM; CLONAZEPAM; CLOZAPINE; DESIPRAMINE; DONEPEZIL; GALANTAMINE; HALOPERIDOL; LEVODOPA; MELATONIN; MEMANTINE; METHYLPHENIDATE; MODAFINIL; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PLACEBO; PRAMIPEXOLE; QUETIAPINE; RASAGILINE; RISPERIDONE; RIVASTIGMINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; UNINDEXED DRUG; VENLAFAXINE;

ATTENTION; BIOETHICS; BRAIN DEPTH STIMULATION; COGNITIVE DEFECT; COGNITIVE THERAPY; DAILY LIFE ACTIVITY; DAYTIME SOMNOLENCE; DEPRESSION; DEPTH PERCEPTION; DRUG DOSE REGIMEN; DRUG MONITORING; EXECUTIVE FUNCTION; GLOBUS PALLIDUS; HUMAN; KINESIOTHERAPY; MAJOR DEPRESSION; MEDICAL DECISION MAKING; MEMORY; MENTAL CAPACITY; MENTAL HEALTH; MOOD DISORDER; MOTOR DYSFUNCTION; PARASOMNIA; PARKINSON DISEASE; PHYSIOTHERAPY; PRIORITY JOURNAL; PROTECTION; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESEARCH SUBJECT; REVIEW; VISUAL DISORDER; VISUAL HALLUCINATION; ANIMAL; CAR DRIVING; COGNITION; COGNITION DISORDERS; COMPLICATION; DEMENTIA; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY;

ANIMALS; AUTOMOBILE DRIVING; COGNITION; COGNITION DISORDERS; DEMENTIA; HUMANS; PARKINSON DISEASE;

EID: 84898794084     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25870     Document Type: Review

References (112)

1. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22:1689-1707; quiz, 1837.
2. Litvan I, Goldman JG, Tröster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012;27:349-356.
3. Nocera JR, Price C, Fernandez HH, et al. Tests of dorsolateral frontal function correlate with objective tests of postural stability in early to moderate stage Parkinson's disease. Parkinsonism Relat Disord 2010;16:590-594.
4. Yarnall A, Rochester L, Burn DJ. The interplay of cholinergic function, attention, and falls in Parkinson's disease. Mov Disord 2011;26:2496-2503.
5. Hindle JV, Petrelli A, Clare L, Kalbe E. Nonpharmacological enhancement of cognitive function in Parkinson's disease: a systematic review. Mov Disord 2013;28:1034-1049.
6. París AP, Saleta HG, de la Cruz Crespo Maraver M, et al. Blind randomized controlled study of the efficacy of cognitive training in Parkinson's disease. Mov Disord 2011;26:1251-1258.
7. Nombela C, Bustillo PJ, Castell PF, Sanchez L, Medina V, Herrero MT. Cognitive rehabilitation in Parkinson's disease: evidence from neuroimaging. Front Neurol 2011;2:82.
8. Sammer G, Reuter I, Hullmann K, Kaps M, Vaitl D. Training of executive functions in Parkinson's disease. J Neurol Sci 2006;248:115-119.
9. Ridgel AL, Kim CH, Fickes EJ, Muller MD, Alberts JL. Changes in executive function after acute bouts of passive cycling in Parkinson's disease. J Aging Phys Act 2011;19:87-98.
10. Cruise KE, Bucks RS, Loftus AM, Newton RU, Pegoraro R, Thomas MG. Exercise and Parkinson's: benefits for cognition and quality of life. Acta Neurol Scand 2011;123:13-19.
11. Pal E, Nagy F, Aschermann Z, Balazs E, Kovacs N. The impact of left prefrontal repetitive transcranial magnetic stimulation on depression in Parkinson's disease: a randomized, double-blind, placebo-controlled study. Mov Disord 2010;25:2311-2317.
12. Boggio PS, Ferrucci R, Rigonatti SP, et al. Effects of transcranial direct current stimulation on working memory in patients with Parkinson's disease. J Neurol Sci 2006;249:31-38.
13. Hanagasi HA, Gurvit H, Unsalan P, et al. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study. Mov Disord 2011;26:1851-1858.
14. Grace J, Amick MM, Friedman JH. A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease. J Neurol Neurosurg Psychiatry 2009;80:18-23.
15. Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003;60:1745-1748.
16. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509-2518.
17. Wesnes KA, McKeith I, Edgar C, Emre M, Lane R. Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology 2005;65:1654-1656.
18. Burn D, Emre M, McKeith I, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 2006;21:1899-1907.
19. Poewe W, Wolters E, Emre M, et al. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Mov Disord 2006;21:456-461.
20. Oertel W, Poewe W, Wolters E, et al. Effects of rivastigmine on tremor and other motor symptoms in patients with Parkinson's disease dementia: a retrospective analysis of a double-blind trial and an open-label extension. Drug Saf 2008;31:79-94.
21. Dubois B, Tolosa E, Katzenschlager R, et al. Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord 2012;27:1230-1238.
22. Aarsland D, Mosimann UP, McKeith IG. Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol 2004;17:164-171.
23. Thomas AJ, Burn DJ, Rowan EN, et al. A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry 2005;20:938-944.
24. Minett TSC, Thomas A, Wilkinson LM, et al. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia. Int J Geriatr Psychiatry 2003;18:988-993.
25. Maidment I, Fox C, Boustani M. Cholinesterase inhibitors for Parkinson's disease dementia. Cochrane Database Syst Rev 2006;CD004747.
26. Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev 2012;3:CD006504.
27. Leroi I, Overshott R, Byrne EJ, Daniel E, Burns A. Randomized controlled trial of memantine in dementia associated with Parkinson's disease. Mov Disord 2009;24:1217-1221.
28. Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009;8:613-618.
29. Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9:969-977.
30. Molloy SA, Rowan EN, O'Brien JT, McKeith IG, Wesnes K, Burn DJ. Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2006;77:1323-1328.
31. Aarsland D, Larsen JP, Karlsen K, Lim NG, Tandberg E. Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 1999;14:866-874.
32. Aarsland D, Perry R, Larsen JP, et al. Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. J Clin Psychiatry 2005;66:633-637.
33. Fernandez HH, Okun MS, Rodriguez RL, et al. Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study. Int J Neurosci. 2009;119:2196-2205.
34. Morgante L, Epifanio A, Spina E, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 2004;27:153-156.
35. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. The Parkinson Study Group. N Engl J Med 1999;340:757-763.
36. Clozapine in drug-induced psychosis in Parkinson's disease. The French Clozapine Parkinson Study Group. Lancet 1999;353:2041-2042.
37. Coward DM, Imperato A, Urwyler S, White TG. Biochemical and behavioural properties of clozapine. Psychopharmacology (Berl) 1989;99(Suppl):S6-S12.
38. Weintraub D, Morales KH, Moberg PJ, et al. Antidepressant studies in Parkinson's disease: a review and meta-analysis. Mov Disord 2005;20:1161-1169.
39. Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:996-1002.
40. Devos D, Dujardin K, Poirot I, et al. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2008;23:850-857.
41. Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009;72:886-892.
42. Richard IH, McDermott MP, Kurlan R, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 2012;78:1229-1236.
43. Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9:573-580.
44. Boeve BF, Silber MH, Ferman TJ, Lucas JA, Parisi JE. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord 2001;16:622-630.
45. Olson EJ, Boeve BF, Silber MH. Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. Brain 2000;123:331-339.
46. Lapierre O, Montplaisir J. Polysomnographic features of REM sleep behavior disorder: development of a scoring method. Neurology 1992;42:1371-1374.
47. Boeve BF, Silber MH, Ferman TJ. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med 2003;4:281-284.
48. Di Giacopo R, Fasano A, Quaranta D, Della Marca G, Bove F, Bentivoglio AR. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease. Mov Disord 2012;27:559-561.
49. Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord. 2003;18:287-293.
50. Nieves AV, Lang AE. Treatment of excessive daytime sleepiness in patients with Parkinson's disease with modafinil. Clin Neuropharmacol 2002;25:111-114.
51. Ondo WG, Fayle R, Atassi F, Jankovic J. Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry 2005;76:1636-1639.
52. Leroi I, Pantula H, McDonald K, Harbishettar V. Neuropsychiatric symptoms in Parkinson's disease with mild cognitive impairment and dementia. Parkinsons Dis 2012;2012:308097.
53. Devos D, Moreau C, Maltête D, et al. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial. J Neurol Neurosurg Psychiatry 2013 NOv 11. doi: 10.1136/jnnp-2013-306439.
54. Chatterjee A, Fahn S. Methylphenidate treats apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2002;14:461-462.
55. Uc EY, Rizzo M, Johnson AM, et al. Real-life driving outcomes in Parkinson disease. Neurology 2011;76:1894-1902.
56. Martin AJ, Marottoli R, O'Neill D. Driving assessment for maintaining mobility and safety in drivers with dementia. Cochrane Database Syst Rev 2013;8:CD006222.
57. Hopkins RW, Kilik L, Day DJA, Rows C, Tseng H. Driving and dementia in Ontario: a quantitative assessment of the problem. Can J Psychiatry 2004;49:434-438.
58. Devos H, Vandenberghe W, Tant M, et al. Driving and off-road impairments underlying failure on road testing in Parkinson's disease. Mov Disord 2013;28:1949-1956.
59. Uc EY, Rizzo M, Johnson AM, Dastrup E, Anderson SW, Dawson JD. Road safety in drivers with Parkinson disease. Neurology 2009;73:2112-2119.
60. Uc EY, Rizzo M. Driving and neurodegenerative diseases. Curr Neurol Neurosci Rep 2008;8:377-383.
61. Lee JD, Strayer DL. Preface to the special section on driver distraction. Hum Factors 2004;46:583-586.
62. Ranchet M, Paire-Ficout L, Uc EY, Bonnard A, Sornette D, Broussolle E. Impact of specific executive functions on driving performance in people with Parkinson's disease. Mov Disord 2013;28:1941-1948.
63. Ranchet M, Paire-Ficout L, Marin-Lamellet C, Laurent B, Broussolle E. Impaired updating ability in drivers with Parkinson's disease. J Neurol Neurosurg Psychiatry 2011;82:218-223.
64. Uc EY, Rizzo M, Anderson SW, Qian S, Rodnitzky RL, Dawson JD. Visual dysfunction in Parkinson disease without dementia. Neurology 2005;65:1907-1913.
65. Crizzle AM, Classen S, Uc EY. Parkinson disease and driving: an evidence-based review. Neurology 2012;79:2067-2074.
66. Uc EY, Rizzo M, Anderson SW, Dastrup E, Sparks JD, Dawson JD. Driving under low-contrast visibility conditions in Parkinson disease. Neurology 2009;73:1103-1110.
67. Devos H, Vandenberghe W, Nieuwboer A, et al. Validation of a screening battery to predict driving fitness in people with Parkinson's disease. Mov Disord 2013;28:671-674.
68. Devos H, Vandenberghe W, Nieuwboer A, Tant M, Baten G, De Weerdt W. Predictors of fitness to drive in people with Parkinson disease. Neurology 2007;69:1434-1441.
69. Zesiewicz TA, Cimino CR, Malek AR, et al. Driving safety in Parkinson's disease. Neurology 2002;59:1787-1788.
70. Stolwyk RJ, Triggs TJ, Charlton JL, Iansek R, Bradshaw JL. Impact of internal versus external cueing on driving performance in people with Parkinson's disease. Mov Disord 2005;20:846-857.
71. Uc EY, Rizzo M, Dastrup E, et al. Impaired curve negotiation in drivers with Parkinson's disease. Turk Noroloji Dergisi 2009;15:10-18.
72. Uc EY, Rizzo M, Anderson SW, Sparks JD, Rodnitzky RL, Dawson JD. Impaired navigation in drivers with Parkinson's disease. Brain 2007;130:2433-2440.
73. Uc EY, Rizzo M, Anderson SW, Sparks J, Rodnitzky RL, Dawson JD. Impaired visual search in drivers with Parkinson's disease. Ann Neurol 2006;60:407-413.
74. Stolwyk RJ, Triggs TJ, Charlton JL, Moss S, Iansek R, Bradshaw JL. Effect of a concurrent task on driving performance in people with Parkinson's disease. Mov Disord 2006;21:2096-2100.
75. Uc EY, Rizzo M, Anderson SW, Sparks JD, Rodnitzky RL, Dawson JD. Driving with distraction in Parkinson disease. Neurology 2006;67:1774-1780.
76. Crizzle AM, Classen S, Lanford DN, et al. Postural/gait and cognitive function as predictors of driving performance in Parkinson's disease. J Parkinsons Dis 2013;3:153-160.
77. Cordell R, Lee HC, Granger A, Vieira B, Lee AH. Driving assessment in Parkinson's disease-a novel predictor of performance? Mov Disord. 2008;23:1217-1222.
78. Heikkilä VM, Turkka J, Korpelainen J, Kallanranta T, Summala H. Decreased driving ability in people with Parkinson's disease. J Neurol Neurosurg Psychiatry 1998;64:325-330.
79. Classen S, McCarthy DP, Shechtman O, et al. Useful field of view as a reliable screening measure of driving performance in people with Parkinson's disease: results of a pilot study. Traffic Inj Prev 2009;10:593-598.
80. Homann CN, Suppan K, Homann B, Crevenna R, Ivanic G, Ruzicka E. Driving in Parkinson's disease-a health hazard? J Neurol 2003;250:1439-1446.
81. Klimkeit EI, Bradshaw JL, Charlton J, Stolwyk R, Georgiou-Karistianis N. Driving ability in Parkinson's disease: current status of research. Neurosci Biobehav Rev 2009;33:223-231.
82. Dubinsky RM, Gray C, Husted D, et al. Driving in Parkinson's disease. Neurology 1991;41:517-520.
83. Meindorfner C, Körner Y, Möller JC, Stiasny-Kolster K, Oertel WH, Krüger HP. Driving in Parkinson's disease: mobility, accidents, and sudden onset of sleep at the wheel. Mov Disord 2005;20:832-842.
84. Crizzle AM, Myers AM, Almeida QJ. Self-regulatory practices of drivers with Parkinson's disease: accuracy of patient reports. Parkinsonism Relat Disord 2013;19:176-180.
85. Uc EY. Driving in Parkinson's disease: decision on driving fitness a joint process. Available at: http://www.movementdisorders.org/monthly_edition/2010/06/driving_in_pd.php. Accessed December 4, 2013.
86. Martinez-Ramirez D, Okun MS. Rationale and clinical pearls for primary care doctors referring patients for deep brain stimulation. Gerontology 2013;60:38-48.
87. Daniels C, Krack P, Volkmann J, et al. Risk factors for executive dysfunction after subthalamic nucleus stimulation in Parkinson's disease. Mov Disord 2010;25:1583-1589.
88. Smeding HMM, Speelman JD, Huizenga HM, Schuurman PR, Schmand B. Predictors of cognitive and psychosocial outcome after STN DBS in Parkinson's disease. J Neurol Neurosurg Psychiatry 2011;82:754-760.
89. Parsons TD, Rogers SA, Braaten AJ, Woods SP, Tröster AI. Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a meta-analysis. Lancet Neurol 2006;5:578-588.
90. Deuschl G, Paschen S, Witt K. Clinical outcome of deep brain stimulation for Parkinson's disease. Handb Clin Neurol 2013;116:107-128.
91. Okun MS. Deep-brain stimulation for Parkinson's disease. N Engl J Med 2012;367:1529-1538.
92. Follett KA, Weaver FM, Stern M, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med 2010;362:2077-2091.
93. Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006;355:896-908.
94. Williams AE, Arzola GM, Strutt AM, Simpson R, Jankovic J, York MK. Cognitive outcome and reliable change indices two years following bilateral subthalamic nucleus deep brain stimulation. Parkinsonism Relat Disord 2011;17:321-327.
95. Ardouin C, Pillon B, Peiffer E, et al. Bilateral subthalamic or pallidal stimulation for Parkinson's disease affects neither memory nor executive functions: a consecutive series of 62 patients. Ann Neurol 1999;46:217-223.
96. Zangaglia R, Pacchetti C, Pasotti C, et al. Deep brain stimulation and cognitive functions in Parkinson's disease: a three-year controlled study. Mov Disord 2009;24:1621-1628.
97. Volkmann J, Allert N, Voges J, Sturm V, Schnitzler A, Freund HJ. Long-term results of bilateral pallidal stimulation in Parkinson's disease. Ann Neurol 2004;55:871-875.
98. Rouaud T, Dondaine T, Drapier S, et al. Pallidal stimulation in advanced Parkinson's patients with contraindications for subthalamic stimulation. Mov Disord 2010;25:1839-1846.
99. Rodriguez-Oroz MC, Obeso JA, Lang AE, et al. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain 2005;128:2240-2249.
100. Weaver FM, Follett KA, Stern M, et al. Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes. Neurology 2012;79:55-65.
101. Okun MS, Fernandez HH, Wu SS, et al. Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trial. Ann Neurol 2009;65:586-595.
102. Dymek MP, Atchison P, Harrell L, Marson DC. Competency to consent to medical treatment in cognitively impaired patients with Parkinson's disease. Neurology 2001;56:17-24.
103. Martin RC, Okonkwo OC, Hill J, et al. Medical decision-making capacity in cognitively impaired Parkinson's disease patients without dementia. Mov Disord 2008;23:1867-1874.
104. Karlawish J, Cary M, Moelter ST, et al. Cognitive impairment and PD patients' capacity to consent to research. Neurology 2013;81:801-807.
105. Schrag A. Driving in Parkinson's disease. J Neurol Neurosurg Psychiatry 2005;76:159.
106. Ford PJ. Vulnerable brains: research ethics and neurosurgical patients. J Law Med Ethics 2009;37:73-82.
107. Appelbaum PS, Grisso T. Assessing patients' capacities to consent to treatment. N Engl J Med 1988;319:1635-1638.
108. Farris S, Ford P, DeMarco J, Giroux ML. Deep brain stimulation and the ethics of protection and caring for the patient with Parkinson's dementia. Mov Disord 2008;23:1973-1976.
109. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013;310:2191-2194.
110. The Belmont Report. The Belmont Report. 1979. Available at: http://www.hhs.gov/ohrp/humansubjects/guidance/belmont.html. Accessed January 21, 2014.
111. Kim SYH, Kim HM, Knopman DS, De Vries R, Damschroder L, Appelbaum PS. Effect of public deliberation on attitudes toward surrogate consent for dementia research. Neurology 2011;77:2097-2104.
112. Karlawish J, Rubright J, Casarett D, Cary M, Ten Have T, Sankar P. Older adults' attitudes toward enrollment of non-competent subjects participating in Alzheimer's research. Am J Psychiatry 2009;166:182-188.